[Cardiovascular risks of Cox-2-antagonists. Opinion on the marketed name rofecoxib, and its market-withdrawn valdecoxib and the actual therapeutic restrictions].
Bolten
W W
WW
Reiter
S
S
D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000517:prevention & control*; D003257:Consumer Product Safety; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D017277:Drug Approval; D005858:Germany; D006801:Humans; D007555:Isoxazoles / Q000009:adverse effects* / Q000627:therapeutic use; D007783:Lactones / Q000009:adverse effects* / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D012216:Rheumatic Diseases / Q000188:drug therapy*; D013449:Sulfonamides / Q000009:adverse effects* / Q000627:therapeutic use; D013450:Sulfones / Q000009:adverse effects* / Q000627:therapeutic use; D000096926:Benzenesulfonamides
D018501:Antirheumatic Agents; D016861:Cyclooxygenase Inhibitors; D007555:Isoxazoles; D007783:Lactones; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; C406224:valdecoxib; D000096926:Benzenesulfonamides